AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22385472 — intervention group
Group type: EXPERIMENTAL
Intervention: Acotiamide (100 mg t.i.d.)
Number of subjects: 34
Study 22385472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 20446587 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 2539
Study 20446587 — intervention group
Group type: COMPARATOR
Intervention: Non-aspirin (control group)
Number of subjects: 2539
Study 20446587 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapidil 300 mg/day
Number of subjects: 2539
Study 20446587 — intervention group
Group type: COMPARATOR
Intervention: No antiplatelets (control group)
Number of subjects: 2539
Study 18346011 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Number of subjects: 0
Study 16673837 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms measured using the Center for Epidemiologic Studies Depression Scale (CES-D)
Number of subjects: 183
Study 16673837 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic control measured by HbA1c, lipids, blood pressure
Number of subjects: 183
Study 12895190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomethiazole (68 mg kg(‐1) as a three-phase i.v. infusion over 24 h)
Number of subjects: 1546
Study 12895190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1546
Study 10865417 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency anemia (IDA)
Number of subjects: 28
Study 10865417 — intervention group
Group type: EXPERIMENTAL
Intervention: G6PD deficiency (G6PD def.)
Number of subjects: 28
Study 9108693 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations of entitativity for individual targets
Number of subjects: 0
Study 9108693 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations of entitativity for group targets
Number of subjects: 0
Study 9108693 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall, memory‐judgment correlation, and illusory correlation measures
Number of subjects: 0
Study 8213104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg)
Number of subjects: 1073
Study 8213104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1073
Study 3747025 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler technique
Number of subjects: 150
Study 3747025 — intervention group
Group type: COMPARATOR
Intervention: Anterior route (standard technique)
Number of subjects: 150
Study 3747025 — intervention group
Group type: COMPARATOR
Intervention: Posterior route (standard technique)
Number of subjects: 150
Study 29635842 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex Border Sacrum and Mepilex Heel dressings applied to sacrum and heels (n = 138)
Number of subjects: 288
Study 29635842 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 150)
Number of subjects: 288
Study 29635842 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex Border Sacrum and Mepilex Heel dressings
Number of subjects: 288
Study 28825195 — intervention group
Group type: EXPERIMENTAL
Intervention: CIM treatments (≥4 treatments, ≤30 days apart)
Number of subjects: 106
Study 28825195 — intervention group
Group type: EXPERIMENTAL
Intervention: CIM treatments (AIC group)
Number of subjects: 106
Study 28825195 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 26139583 — intervention group
Group type: EXPERIMENTAL
Intervention: Natriuretic peptide-based screening and collaborative cardiovascular care
Number of subjects: 1054
Study 23123166 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal approach of musculoskeletal and obstetric management (MOM)
Number of subjects: 169
Study 23123166 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetric care
Number of subjects: 169
Study 22319753 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 17
Study 22319753 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide (CH)
Number of subjects: 17
Study 18489634 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oxycodone/650 mg acetaminophen
Number of subjects: 16
Study 18489634 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hydrocodone/650 mg acetaminophen
Number of subjects: 16
Study 18489634 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oxycodone/325 mg acetaminophen
Number of subjects: 16
Study 18489634 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg hydrocodone/325 mg acetaminophen
Number of subjects: 16
Study 18489634 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg acetaminophen
Number of subjects: 16
Study 18489634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15972889 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate endpoint (tumor response)
Number of subjects: 0
Study 15972889 — intervention group
Group type: COMPARATOR
Intervention: Standard meta-analysis using only true endpoints
Number of subjects: 0
Study 15972889 — intervention group
Group type: COMPARATOR
Intervention: Clinically meaningful difference in true endpoints
Number of subjects: 0
Study 14710262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (Group R, n=25)
Number of subjects: 50
Study 14710262 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (Group B, n=25)
Number of subjects: 50
Study 14710262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (Group R)
Number of subjects: 50
Study 14710262 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (Group B)
Number of subjects: 50
Study 10924865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 349
Study 10924865 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 349
Study 10924865 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 349
Study 8690107 — intervention group
Group type: EXPERIMENTAL
Intervention: GH‐releasing hormone (GH‐RH) (1 mg/kg body weight)
Number of subjects: 18
Study 8690107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg by mouth)
Number of subjects: 18
Study 8690107 — intervention group
Group type: EXPERIMENTAL
Intervention: GH‐RH plus arginine
Number of subjects: 18
Study 8690107 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (30 g infused IV over a 30‐minute period)
Number of subjects: 18
Study 8690107 — intervention group
Group type: EXPERIMENTAL
Intervention: GH‐RH plus pyridostigmine
Number of subjects: 18
Study 8690107 — intervention group
Group type: COMPARATOR
Intervention: Basal hormonal values
Number of subjects: 18
Study 8690107 — intervention group
Group type: COMPARATOR
Intervention: Insulin growth factor‐I levels
Number of subjects: 18
Study 1869595 — intervention group
Group type: COMPARATOR
Intervention: Flosequinan
Number of subjects: 22
Study 1869595 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 22
Study 1869595 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 22
Study 6630328 — intervention group
Group type: EXPERIMENTAL
Intervention: Senokot
Number of subjects: 40
Study 6630328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6630328 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 40
Study 31955642 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic Global Impression of Change (PGIC) Scale
Number of subjects: 1700
Study 31955642 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of cerebral ischemia
Number of subjects: 1700
Study 31955642 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of intracranial hemorrhage
Number of subjects: 1700
Study 29171557 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised structured aerobic exercise training programme, routine medication and dietary plan for 25 weeks at 3 days per week
Number of subjects: 102
Study 29171557 — intervention group
Group type: COMPARATOR
Intervention: Routine medication and dietary plan
Number of subjects: 102
Study 26606990 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty (HA)
Number of subjects: 60
Study 26606990 — intervention group
Group type: COMPARATOR
Intervention: Cementless hemiarthroplasty (HA)
Number of subjects: 60
Study 24033087 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingogram (HSG) with lipiodol
Number of subjects: 296
Study 22959311 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar vessel sealing system (BVSS)
Number of subjects: 116
Study 22959311 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 116
Study 18923193 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail invitation mode
Number of subjects: 0
Study 18923193 — intervention group
Group type: EXPERIMENTAL
Intervention: Retired adults
Number of subjects: 0
Study 18923193 — intervention group
Group type: COMPARATOR
Intervention: Risk-focused message
Number of subjects: 0
Study 17334275 — intervention group
Group type: EXPERIMENTAL
Intervention: Category fluency (CF) test (animals/min) for illiterates
Number of subjects: 205
Study 17334275 — intervention group
Group type: EXPERIMENTAL
Intervention: Category fluency (CF) test (animals/min) for 1 to 3 years education
Number of subjects: 205
Study 17334275 — intervention group
Group type: EXPERIMENTAL
Intervention: Category fluency (CF) test (animals/min) for 4 to 7 years education
Number of subjects: 205
Study 17334275 — intervention group
Group type: EXPERIMENTAL
Intervention: Category fluency (CF) test (animals/min) for >=8 years education
Number of subjects: 205
Study 15754699 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with oral laxative (lactulose 66.7%), metronidazole, and topical glyceryl-trinitrate ointment at 0.2% pre and postoperative
Number of subjects: 30
Study 15754699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11600528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release recombinant human GH at 1.5 mg/kg once monthly
Number of subjects: 74
Study 11600528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release recombinant human GH at 0.75 mg/kg twice monthly
Number of subjects: 74
Study 11600528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release recombinant human GH
Number of subjects: 74
Study 11600528 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 74
Study 9849385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound transmission velocity (UTV)
Number of subjects: 759
Study 9849385 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous evaluation of BMD and UTV
Number of subjects: 759
Study 9849385 — intervention group
Group type: EXPERIMENTAL
Intervention: UTV in a selected subgroup of healthy and fractured women paired for BMD (144 pairs)
Number of subjects: 759
Study 9849385 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous use of BMD and UTV
Number of subjects: 759
Study 8834635 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotic personality type in patients with alopecia areata
Number of subjects: 55
Study 8834635 — intervention group
Group type: COMPARATOR
Intervention: Control group of volunteers
Number of subjects: 55
Study 2213286 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0
Study 2213286 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide with potassium-sparing agent
Number of subjects: 0
Study 2213286 — intervention group
Group type: COMPARATOR
Intervention: Other antihypertensive agents
Number of subjects: 0
Study 44015 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioproperazine (3 x 3 mg/day)
Number of subjects: 0
Study 44015 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride (3 x 100 mg/day)
Number of subjects: 0
Study 44015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31605208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral water baths (20 g/L)
Number of subjects: 145
Study 31605208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral water baths (40 g/L)
Number of subjects: 145
Study 31605208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral water baths (60 g/L)
Number of subjects: 145
Study 31605208 — intervention group
Group type: COMPARATOR
Intervention: Tap water procedures
Number of subjects: 145
Study 31605208 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 145
Study 31605208 — intervention group
Group type: EXPERIMENTAL
Intervention: All mineral water groups
Number of subjects: 145
Study 31605208 — intervention group
Group type: COMPARATOR
Intervention: Mineral water baths vs. tap water
Number of subjects: 145
Study 31605208 — intervention group
Group type: EXPERIMENTAL
Intervention: Single balneotherapy procedure
Number of subjects: 145
Study 31327147 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Carbomer 980 Gel
Number of subjects: 0
Study 31327147 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 27522605 — intervention group
Group type: EXPERIMENTAL
Intervention: Seabuckthorn seed oil at a daily dose of 0.75 ml for 30 days
Number of subjects: 106
Study 27522605 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil placebo
Number of subjects: 106
Study 25929560 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enzalutamide 160 mg
Number of subjects: 41
Study 24469972 — intervention group
Group type: EXPERIMENTAL
Intervention: 300,000 IU intramuscular cholecalciferol
Number of subjects: 153
Study 24469972 — intervention group
Group type: EXPERIMENTAL
Intervention: 25,000 IU oral cholecalciferol monthly
Number of subjects: 153
Study 24469972 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 153
Study 22930004 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 000 IU hCG and standard luteal phase support (Protocol A)
Number of subjects: 4
Study 22930004 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin 0.2 mg) followed by 1500 IU hCG 35 h after triggering final oocyte maturation and standard luteal phase support (Protocol B)
Number of subjects: 4
Study 22930004 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin 0.2 mg) and standard luteal phase support (Protocol C)
Number of subjects: 4
Study 22930004 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin 0.2 mg) without luteal phase support (Protocol D)
Number of subjects: 4
Study 20616746 — intervention group
Group type: EXPERIMENTAL
Intervention: Flortec (Lactobacillus paracasei B 21060)
Number of subjects: 174
Study 20616746 — intervention group
Group type: COMPARATOR
Intervention: FlorVis GG (lactobacillus GG)
Number of subjects: 174
Study 17572248 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 812
Study 17572248 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and strength training
Number of subjects: 812
Study 16079649 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 20
Study 16079649 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 11777363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo
Number of subjects: 0
Study 11777363 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort
Number of subjects: 0
Study 11777363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng
Number of subjects: 0
Study 11777363 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea
Number of subjects: 0
Study 11777363 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto
Number of subjects: 0
Study 11777363 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 0
Study 10597869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10mg once daily for 2 to 3 weeks
Number of subjects: 0
Study 10597869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20mg once daily for 2 to 3 weeks
Number of subjects: 0
Study 10597869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10mg twice daily for 3 weeks
Number of subjects: 0
Study 10597869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20mg once daily for 3 weeks
Number of subjects: 0
Study 10597869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7703058 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein patch closure
Number of subjects: 27
Study 7703058 — intervention group
Group type: COMPARATOR
Intervention: Primary CEA closure
Number of subjects: 27
Study 2199643 — intervention group
Group type: EXPERIMENTAL
Intervention: Similac Special Care formula with a 50:50 carbohydrate blend of glucose polymers and lactose (n = 8)
Number of subjects: 18
Study 2199643 — intervention group
Group type: COMPARATOR
Intervention: Similac Special Care formula with 100% carbohydrate as lactose (n = 10)
Number of subjects: 18
Study 949102 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (Ethrane)
Number of subjects: 13
Study 949102 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 13
Study 949102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 13
Study 29618071 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigation (image guidance)
Number of subjects: 203
Study 29618071 — intervention group
Group type: COMPARATOR
Intervention: No image guidance (control group)
Number of subjects: 203
Study 28822635 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocomposite interference screws
Number of subjects: 51
Study 23549516 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol (10 mg twice per day)
Number of subjects: 48
Study 23549516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23405020 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physical therapy (respiratory and global exercises) for 2-3 weeks before surgery
Number of subjects: 32
Study 23405020 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physical therapy
Number of subjects: 32
Study 23405020 — intervention group
Group type: COMPARATOR
Intervention: Control group (await operation without engaging in practicing)
Number of subjects: 32
Study 23405020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (preoperative physical therapy)
Number of subjects: 32
Study 21989099 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight monitoring and recording (measured, recorded, and announced twice a week for 3 months)
Number of subjects: 79
Study 21989099 — intervention group
Group type: COMPARATOR
Intervention: Control group (weight measured and recorded once at the beginning and once at the end of the study)
Number of subjects: 79
Study 18829219 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy associated with patient education (spa treatment course in La Léchère) consisting of four balneology sessions per day, six days a week for three weeks, and three educational workshops.
Number of subjects: 59
Study 18829219 — intervention group
Group type: COMPARATOR
Intervention: Control group received spa treatment starting at day 365 (after the treatment group).
Number of subjects: 59
Study 16213470 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 16
Study 16213470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15541857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleavage stage embryo transfer (2-3 days culture)
Number of subjects: 144
Study 15541857 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst stage embryo transfer (5-6 days culture)
Number of subjects: 144
Study 15541857 — intervention group
Group type: EXPERIMENTAL
Intervention: Good quality embryo transfer (day 2-3)
Number of subjects: 144
Study 15541857 — intervention group
Group type: EXPERIMENTAL
Intervention: Good quality embryo transfer (day 5-6)
Number of subjects: 144
Study 11328684 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute exposure to a previously recorded 10 kHz-sferics impulse with a pulse repetition frequency of 1 to 3 Hz.
Number of subjects: 80
Study 11328684 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 80
Study 9218070 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee (300 mL)
Number of subjects: 17
Study 9218070 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (300 mL)
Number of subjects: 17
Study 8525856 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300-600 mg/day)
Number of subjects: 55
Study 8525856 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 55
Study 8525856 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (Moclobemide and Sertraline)
Number of subjects: 55
Study 8525856 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 55
Study 2492322 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nitroglycerin patches (10 mg/day)
Number of subjects: 36
Study 2492322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent nitroglycerin patches (10 mg/day) for 18 h/day with 6 h off
Number of subjects: 36
Study 2492322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent nitroglycerin patches (10 mg/day) for 14 h/day with 10 h off
Number of subjects: 36
Study 2492322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 2492322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment (10 h off)
Number of subjects: 36
Study 2492322 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 36
Study 4623522 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 9
Study 4623522 — intervention group
Group type: COMPARATOR
Intervention: Control (without phenytoin)
Number of subjects: 9
Study 30924702 — intervention group
Group type: EXPERIMENTAL
Intervention: SPN-812 200 mg/day
Number of subjects: 222
Study 30924702 — intervention group
Group type: EXPERIMENTAL
Intervention: SPN-812 300 mg/day
Number of subjects: 222
Study 30924702 — intervention group
Group type: EXPERIMENTAL
Intervention: SPN-812 400 mg/day
Number of subjects: 222
Study 30924702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 30734832 — intervention group
Group type: EXPERIMENTAL
Intervention: Darmocare Pre® (inulin and fructooligosaccharides) for 13 weeks
Number of subjects: 50
Study 30734832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin) for 13 weeks
Number of subjects: 50